• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Pharmacokinetics and mechanism of action of detoxifying low-molecular-weight thiols.低分子量硫醇解毒的药代动力学及作用机制
J Cancer Res Clin Oncol. 1984;108(1):87-97. doi: 10.1007/BF00390979.
2
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
3
Management of urinary stones by experts in stone disease (ESD 2025).结石病专家对尿路结石的管理(2025年结石病专家共识)
Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085.
4
Ideas and reality in the development of cancer chemotherapeutic agents, with particular reference to oxazaphosphorine cytostatics.癌症化疗药物研发中的理念与现实,特别提及氮杂磷三环类细胞抑制剂
J Cancer Res Clin Oncol. 1986;111(1):1-12. doi: 10.1007/BF00402768.
5
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
6
Sexual Harassment and Prevention Training性骚扰与预防培训
7
Detoxification of urotoxic oxazaphosphorines by sulfhydryl compounds.巯基化合物对尿毒性氮杂磷类化合物的解毒作用。
J Cancer Res Clin Oncol. 1981;100(3):311-20. doi: 10.1007/BF00410691.
8
Surveillance for Violent Deaths - National Violent Death Reporting System, 50 States, the District of Columbia, and Puerto Rico, 2022.暴力死亡监测——2022年全国暴力死亡报告系统,50个州、哥伦比亚特区和波多黎各
MMWR Surveill Summ. 2025 Jun 12;74(5):1-42. doi: 10.15585/mmwr.ss7405a1.
9
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.两种现代生存预测工具 SORG-MLA 和 METSSS 在接受手术联合放疗和单纯放疗治疗有症状长骨转移患者中的比较。
Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23.
10
Effect of thiols exported by cancer cells on the stability and growth-inhibitory activity of Pt(IV) complexes.癌细胞分泌的硫醇对铂(IV)配合物稳定性和生长抑制活性的影响
J Cancer Res Clin Oncol. 1999 Dec;125(12):690-6. doi: 10.1007/s004320050335.

引用本文的文献

1
Synthetic and semi-synthetic antioxidants in medicine and food industry: a review.医药和食品工业中的合成与半合成抗氧化剂:综述
Front Pharmacol. 2025 Jul 22;16:1599816. doi: 10.3389/fphar.2025.1599816. eCollection 2025.
2
Plasma TNF-α and Soluble TNF Receptor Levels after Doxorubicin with or without Co-Administration of Mesna-A Randomized, Cross-Over Clinical Study.多柔比星联合或不联合美司钠给药后血浆肿瘤坏死因子-α及可溶性肿瘤坏死因子受体水平——一项随机交叉临床研究
PLoS One. 2015 Apr 24;10(4):e0124988. doi: 10.1371/journal.pone.0124988. eCollection 2015.
3
Analysis of acrolein-derived 1,N2-propanodeoxyguanosine adducts in human leukocyte DNA from smokers and nonsmokers.分析吸烟与非吸烟人群白细胞 DNA 中丙烯醛衍生的 1,N2-丙二脱氧鸟苷加合物。
Chem Res Toxicol. 2011 Jan 14;24(1):119-24. doi: 10.1021/tx100321y. Epub 2010 Nov 22.
4
Pharmacokinetic behaviour of the chemoprotectants BNP7787 and mesna after an i.v. bolus injection in rats.化学保护剂BNP7787和美司钠在大鼠静脉推注后的药代动力学行为。
Br J Cancer. 2004 Apr 19;90(8):1654-9. doi: 10.1038/sj.bjc.6601719.
5
The anti-tumour activity of ifosfamide on heterotransplanted testicular cancer cell lines remains unaltered by the uroprotector mesna.异环磷酰胺对异种移植睾丸癌细胞系的抗肿瘤活性不受尿路保护剂美司钠的影响。
Br J Cancer. 1994 May;69(5):863-7. doi: 10.1038/bjc.1994.167.
6
Ifosfamide clinical pharmacokinetics.异环磷酰胺的临床药代动力学。
Clin Pharmacokinet. 1994 Jun;26(6):439-56. doi: 10.2165/00003088-199426060-00003.
7
The role of active metabolites in drug toxicity.活性代谢物在药物毒性中的作用。
Drug Saf. 1994 Aug;11(2):114-44. doi: 10.2165/00002018-199411020-00006.
8
Ideas and reality in the development of cancer chemotherapeutic agents, with particular reference to oxazaphosphorine cytostatics.癌症化疗药物研发中的理念与现实,特别提及氮杂磷三环类细胞抑制剂
J Cancer Res Clin Oncol. 1986;111(1):1-12. doi: 10.1007/BF00402768.
9
VP 16 plus ifosfamide plus cisplatin as salvage therapy in refractory testicular cancer.
Cancer Chemother Pharmacol. 1986;18 Suppl 2:S45-50. doi: 10.1007/BF00647451.
10
Comparative activity of ifosfamide and cyclophosphamide.异环磷酰胺与环磷酰胺的活性比较
Cancer Chemother Pharmacol. 1986;18 Suppl 2:S1-9. doi: 10.1007/BF00647438.

本文引用的文献

1
[Chemotherapy of cancer. Rationale and possibilities].
Med Klin. 1961 Aug 25;56:1421-30.
2
[Principles of toxicological methods].[毒理学方法原理]
Arzneimittelforschung. 1957 Aug;7(8):449-56.
3
[Studies on the toxicity of nitromin; interference of cystein upon nitromin toxicity].
Gan. 1953 Sep;44(2-3):386-9.
4
Effect of delayed administration of citrovorum factor on the antileukemic effectiveness of aminopterin in mice.甲酰四氢叶酸延迟给药对小鼠氨甲蝶呤抗白血病疗效的影响。
Cancer Res. 1954 Jan;14(1):43-8.
5
[Specific chemotherapy of carcinoma of the prostate].[前列腺癌的特异性化疗]
Klin Wochenschr. 1952 Oct 1;30(37-38):882-4. doi: 10.1007/BF01471475.
6
Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention--I. Experimental studies on the urotoxicity of alkylating compounds.氮杂磷三环类细胞抑制剂的尿路毒性及其预防研究——I. 烷基化化合物尿路毒性的实验研究
Eur J Cancer (1965). 1981 Jun;17(6):595-607. doi: 10.1016/0014-2964(81)90261-9.
7
Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention. 2. Comparative study on the uroprotective efficacy of thiols and other sulfur compounds.氧氮磷啶类细胞抑制剂的尿路毒性及其预防研究。2. 硫醇类及其他含硫化合物尿路保护疗效的比较研究。
Eur J Cancer Clin Oncol. 1981 Nov;17(11):1155-63.
8
The control of ifosfamide-induced hematuria with N-acetylcysteine in patients with advanced carcinoma of the lung.N-乙酰半胱氨酸对晚期肺癌患者异环磷酰胺诱导的血尿的控制作用
Semin Oncol. 1982 Dec;9(4 Suppl 1):71-4.
9
N-acetylcysteine and ifosfamide in the treatment of unresectable pancreatic adenocarcinoma and refractory testicular cancer.N-乙酰半胱氨酸与异环磷酰胺治疗不可切除性胰腺腺癌和难治性睾丸癌
Semin Oncol. 1983 Mar;10(1 Suppl 1):72-5.
10
Prophylaxis of ifosfamide toxicity with oral acetylcysteine.口服乙酰半胱氨酸预防异环磷酰胺毒性
Semin Oncol. 1983 Mar;10(1 Suppl 1):66-71.

低分子量硫醇解毒的药代动力学及作用机制

Pharmacokinetics and mechanism of action of detoxifying low-molecular-weight thiols.

作者信息

Brock N, Hilgard P, Pohl J, Ormstad K, Orrenius S

出版信息

J Cancer Res Clin Oncol. 1984;108(1):87-97. doi: 10.1007/BF00390979.

DOI:10.1007/BF00390979
PMID:6746722
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12252865/
Abstract

A number of thiol compounds have been studied with reference to their selective protective action against urotoxic side-effects of oxazaphosphorine cytostatics. The uroprotective capacity is determined exclusively by the pharmacokinetic behavior of the compound. When given PO, all compounds tested were absorbable from the gut. Both thiols and disulfides are rapidly eliminated from the blood, but during their short half-life a number of unknown chemical reactions probably take place to maintain a physiological redox equilibrium. Elimination from the blood plasma occurs via two fundamentally different mechanisms: by distribution throughout the tissues and intracellular uptake or, alternatively, by rapid renal excretion. Most of the compounds tested belong to the first group: N-acetylcysteine, carboxycysteine, disulfiram and its metabolite DDTC, glutathione, WR 2721, etc. Few compounds are quantitatively excreted through the urine: mesna, dimesna, and DA 12. Only these compounds were suitable for selective regional detoxification and for the prevention of oxazaphosphorine-induced urotoxic lesions.

摘要

已经对多种硫醇化合物进行了研究,以探讨它们对氧氮磷啶类细胞抑制剂的泌尿毒性副作用的选择性保护作用。泌尿保护能力完全由化合物的药代动力学行为决定。口服给药时,所有测试的化合物都可从肠道吸收。硫醇和二硫化物都能迅速从血液中消除,但在它们较短的半衰期内,可能会发生一些未知的化学反应以维持生理氧化还原平衡。血浆中的消除通过两种根本不同的机制进行:通过分布到整个组织和细胞内摄取,或者通过快速肾脏排泄。大多数测试的化合物属于第一组:N-乙酰半胱氨酸、羧基半胱氨酸、双硫仑及其代谢产物二乙基二硫代氨基甲酸钠、谷胱甘肽、WR 2721等。很少有化合物通过尿液定量排泄:美司钠、二巯基丁二酸钠和DA 12。只有这些化合物适用于选择性区域解毒和预防氧氮磷啶引起的泌尿毒性损伤。